Table 1.
Characteristics of studies of interferon or pegylated-interferon treatment of chronic HCV-infected hemodialysis patients with long-term HCV RNA outcomes on hemodialysis
| Study, Country, Year | Overall Sample Size (n) | Number with SVR (n) | Number with Long-Term HCV RNA Outcomes (n) | Treatment Dosea | Treatment Duration (mo)b | Long-Term Follow-Up, Median (mo) |
|---|---|---|---|---|---|---|
| Studies with long-term HCV RNA outcomes with interferon | ||||||
| Pol, France, 1995 | 19 | 6 | 6 | 3 | 6 | 17 |
| Raptopoulou-Gigi, Greece, 1995 | 19 | 13 | 13 | 3 | 6 | 8 |
| Okuda, Japan, 1995 | 15 | 8 | 1 | 6 | 6 | 18 |
| Izopet, France, 1997 | 23 | 13 | 12 | 3 | 6 (n = 5) 12 (n = 7) |
28 |
| Fernandez, Argentina, 1997c | 14 | 3 | 3 | 1.5 | 6 | 12 |
| Chan, Hong Kong, 1997 | 11 | 3 | 3 | 3 | 6 | 18 |
| Campistol, Spain, 1999c | 19 | 11 | 11 | 3 | 6 | 20 |
| Huraib, Saudi Arabia, 1999 | 17 | 12 | 2 | 3 | 12 | 10 |
| Espinosa, Spain, 2001 | 13 | 6 | 6 | 3 | 12 | 27 |
| Hanrotel, France, 2001 | 12 | 4 | 2 | 3 | 12 | 24 |
| Kamar, France, 2003 | 55 | 21 | 16 | 3 | 6 (n = 3) 12 (n = 13) |
37 |
| Ozdemir, Turkey, 2004 | 20 | 8 | 8 | 6 (n = 5) 3 (n = 3) |
6 (n = 5) 12 (n = 3) |
64 |
| Mousa, Saudi Arabia, 2004 | 20 | 11 | 10 | 3 RBV (200 TIW) |
6 (n = 6) 12 (n = 4) |
6 |
| Buargub, Libya, 2006 | 35 | 9 | 4 | 3 | 12 | 12 |
| Studies with long-term HCV RNA outcomes with pegylated-interferon | ||||||
| Bruchfeld, Sweden, 2006 | 6 | 3 | 3 | 135 (α-2a), n = 2 50 (α-2b), n = 1 200–300 daily (RBV) |
6 (n = 1) 12 (n = 2) |
23 |
| Amarapurkar, India, 2007 | 6 | 3 | 3 | 1.0/kg (α-2b) | 6 | 12 |
| Ucmaky, Turkey, 2008 | 12 | 9 | 9 | 135 (α-2a) | 12 | 30 |
| Zoppoli, Italy, 2008 | 10 | 2 | 2 | 135 (α-2a) | 12 | 22 |
| Kose, Turkey, 2009 | 26 | 9 | 2 | 135 (α-2a) | 12 | 9 |
| Dzekova, Macedonia, 2009 | 14 | 5 | 5 | 135 (α-2a) | 12 | 18 |
| All hemodialysis | 366 | 159 | 121 | Variable | 6 (n = 60) 12 (n = 61) |
18 |
α-2a, pegylated-interferon alpha-2a; α-2b, pegylated-interferon alpha-2b; RBV, ribavirin; TIW, three times weekly.
Doses presented for interferon are in million units, three times weekly, and for pegylated interferon alpha-2a or 2b are in micrograms, once weekly. When studies used more than one treatment dose, the numbers reported are based on the group with long-term data.
Intended treatment duration in months. When studies used different durations, the numbers reported in parentheses are from the group with long-term data. More recent studies selected treatment duration based on HCV genotype with 12 months of treatment for genotypes 1 or 4 and 6 months for genotypes 2 or 3.
Randomized controlled trial comparing treated patients versus untreated controls. Sample size reported is the treatment group only.